Adaptive clinical trial design allows for modifications to the trial after it begins without damaging the integrity of the study. An adaptive design allows for a more proficient use of capital and resources through shorter timeframes and fewer patients. Using adaptive design sponsor organizations can allocate resources more efficiently without lowering standards and therefore are able to accelerate the clinical development process.
The point at which data is reviewed for an adaptive trial is known as an interim analysis. During the interim analysis, trial organizers review and analyze data before all the “needed” data is collected. This is the pivotal point where an adaptive trial differs from a traditional design. If a sponsor organization notices that something needs to change within their protocol they can make the necessary changes here, without compromising the trial or starting over — ultimately saving time and resources.
The 2nd Adaptive Clinical Trials Symposium will teach cross-functional stakeholders the importance of statistics, data management, and operations through interim analysis for adaptive clinical trials.
Top Five Reasons to Attend
1. Discover best practices for planning and managing an adaptive trial
2. Learn, from true industry experiences, how to get drugs to market faster at less cost
3. Analysis of FDA guidance and tips to navigate through the gray areas associated with an adaptive design
4. Network with peers and top industry professionals in an intimate environment
5. Understand the role of interim analysis in adaptive design
Time: 8:00 am - 5:30 pm
Early Bird Pricing — Register by February 1, 2019: USD 1895.0,
Standard Pricing: USD 2095.0,
Onsite Pricing: USD 2195.0
2nd Adaptive Clinical Trials Symposium
Reviews are public and modifiable.